Gezielt nachschlagen
Suche
Suche startet nach einer kurzen Eingabepause.
20 angezeigte Treffer · Seite 1, keine Gesamtzahl für „Clopidogrel HCS“
Suchtreffer
Begriffe & Kennungen
Clopidogrel HCS
Eintrag öffnenClopidogrel HCS · 4.1 Therapeutic indications · 1
Eintrag öffnenClopidogrel HCS · 4.3 Contraindications · 1
Eintrag öffnenClopidogrel HCS · 4.3 · • Hypersensitivity to the active substance or to any of the excipients listed in section 2 or section 6.1. • S
Eintrag öffnenClopidogrel HCS · 4.4 Special warnings and precautions for use · 1
Eintrag öffnenClopidogrel HCS · 4.5 Interaction with other medicinal products and other forms of interaction · 1
Eintrag öffnenClopidogrel HCS · 4.5 · 6 Apart from the specific medicinal product interaction information described above, interaction studies with
Eintrag öffnenClopidogrel HCS · 4.5 · Acetylsalicylic acid (ASA) ASA did not modify the clopidogrel-mediated inhibition of ADP-induced platelet aggr
Eintrag öffnenClopidogrel HCS · 4.5 · CYP2C8 substrate medicinal products: Clopidogrel has been shown to increase repaglinide exposure in healthy vo
Eintrag öffnenClopidogrel HCS · 4.5 · Data from the CAPRIE study indicate that phenytoin and tolbutamide which are metabolised by CYP2C9 can be safe
Eintrag öffnenClopidogrel HCS · 4.5 · Glycoprotein IIb/IIIa inhibitors Clopidogrel should be used with caution in patients who receive concomitant g
Eintrag öffnenClopidogrel HCS · 4.5 · Heparin In a clinical study conducted in healthy subjects, clopidogrel did not necessitate modification of the
Eintrag öffnenClopidogrel HCS · 4.5 · Inconsistent data on the clinical implications of this pharmacokinetic (PK)/pharmacodynamic (PD) interaction i
Eintrag öffnenClopidogrel HCS · 4.5 · Less pronounced reductions of metabolite exposure has been observed with pantoprazole or lansoprazole. The pla
Eintrag öffnenClopidogrel HCS · 4.5 · Medicinal products associated with bleeding risk: There is an increased risk of bleeding due to the potential
Eintrag öffnenClopidogrel HCS · 4.5 · Medicinal products that are strong or moderate CYP2C19 inhibitors include, for example, omeprazole and esomepr
Eintrag öffnenClopidogrel HCS · 4.5 · NSAIDs In a clinical study conducted in healthy volunteers, the concomitant administration of clopidogrel and
Eintrag öffnenClopidogrel HCS · 4.5 · Oral anticoagulants The concomitant administration of clopidogrel with oral anticoagulants is not recommended
Eintrag öffnenClopidogrel HCS · 4.5 · Other concomitant therapy Since clopidogrel is metabolised to its active metabolite partly by CYP2C19, use of
Eintrag öffnenClopidogrel HCS · 4.5 · Other medicinal products: A number of other clinical studies have been conducted with clopidogrel and other co
Eintrag öffnen